Researchers looked at how different medications affect people with atrial fibrillation who have also experienced a previous brain bleed. They compared two types of treatments: direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs). The goal was to see which treatment performed better in preventing strokes and other serious health issues.
The analysis found that patients taking DOACs had a lower risk of recurring brain bleeds, as well as a lower risk of stroke and death compared to those on VKAs. However, the researchers noted that some of these findings were less consistent when using more conservative statistical methods. Because the evidence is based on observational data, it shows an association rather than a direct cause.
The quality of the evidence for these findings ranges from moderate to very low. Because the results are not definitive, this information should be used to help doctors and patients have better conversations about treatment choices. It does not yet provide enough certainty to change standard medical practices immediately.